Category Archives: Gansu

Gansu Screens Ninth Batch of Drug Sunshine Listing Applications – Only 229 of 595 Pass Formal Review as Appeal Window Closes

Lanzhou, China – 18 Sep 2026 – The Gansu Public Resources Trading Center publicized the formal review results of the ninth batch of new drug sunshine listing applications for 2026, disclosing that of 595 products submitted through the national joint review mechanism (联审通办) and the provincial bidding‑and‑procurement management subsystem as of 10 September 2026, only 229 qualified for platform listing while 366 failed the screening. The publicity period runs 20–22 September 2026, with online appeals due by 24:00 on 22 September 2026.

Policy Snapshot

ItemDetail
AgencyGansu Public Resources Trading Center; supervised by the Gansu Provincial Healthcare Security Bureau
DocumentPublicity of Formal Review Results – Ninth Batch of New Drug Sunshine Listings, 2026
Legal BasisGansu Service Guide for the Drug & Medical Consumables Procurement Management Subsystem (v1.0); Gansu Drug Listing/Delisting Rules
Applications Received595 (national joint review + provincial subsystem, as of 10 Sep 2026)
Passed Formal Review229 (≈ 38.5 % pass rate)
Failed Formal Review366 – itemized in the annexed publicity table (.xls)
Publicity Period20–22 Sep 2026
Appeal Deadline24:00, 22 Sep 2026, online only
ContactsBusiness: 0931‑2909290 / 2909266 / 2909265; Supervision: 0931‑8127609 (Provincial Healthcare Security Bureau)

Review Results & Compliance Requirements

  • Formal Review Outcomes: The 229 qualifying products will proceed to sunshine listing on the provincial platform, subject to completion of the publicity period; the 366 rejected products are listed in the annexed Formal Review Results Publicity Table, giving affected manufacturers a clear, product‑level basis for appeal.
  • Price Declaration Undertakings: Listing prices are self‑declared by enterprises under the good‑faith principle and must not exceed Gansu’s provincial price‑management requirements – placing documentation and pricing integrity squarely on applicants.
  • Cross‑Province Price‑Linkage Rule: If a listed drug’s price is reduced in any other province, the manufacturer must proactively apply for a matching price cut in Gansu within one month – failure to do so triggers suspension of trading qualification, extending the nationwide price‑linkage discipline into Gansu’s procurement channel.
  • Appeals Strictly Online: Objections must be filed via the “Appeal & Query” module under the “New Drug Listing Application” menu of the Gansu National Healthcare Insurance Information Platform procurement subsystem; paper and email submissions are not accepted, and non‑conforming filings will be rejected with any resulting losses borne by the enterprise.

Market Impact & Outlook

  • Selective Gatekeeping: A ≈ 38.5 % pass rate (229 of 595) signals rigorous formal screening in Gansu, reinforcing that completeness and accuracy of submission dossiers – not price alone – determine platform access.
  • National‑Provincial Convergence: The batch combined applications from the national joint review mechanism with the provincial subsystem, reflecting China’s ongoing integration of drug procurement access points across provinces.
  • Pricing Discipline Tightening: The one‑month cross‑province price‑adjustment obligation, backed by trading suspension, aligns Gansu with the hardening nationwide enforcement of external‑reference pricing for listed drugs.
  • Immediate Action Window: With the publicity period and appeal deadline both closing on 22 September 2026, manufacturers among the 366 rejected products face a same‑week turnaround to challenge results or prepare compliant resubmissions in future batches.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding appeal outcomes, listing approvals, price‑adjustment obligations, and trading‑qualification status for drug products in Gansu Province. Actual results may differ due to risks including appeal handling decisions, enterprise remediation progress, and subsequent policy adjustments by the Gansu Public Resources Trading Center and the Provincial Healthcare Security Bureau.-China Health Reform Pulse

Policy Source: https://sjfz.ggzyjy.gansu.gov.cn:19002/#/details-medicine?params=H4sIAAAAAAAAA6tWykxRslIyNLewNDcyNTSyMDc0VaoFAElMeS4WAAAA&pop=true

China’s NHSA Launches Work Plan for First National Medical Insurance Medical Service Catalogue – 13 Clinical Categories in Batch One Reshape Reimbursement Rules for Providers Nationwide

Beijing, China – 16 Sep 2026 – China’s National Healthcare Security Administration (NHSA) released the Work Plan for Formulating the First Batch of the National Basic Medical Insurance Medical Service Item Catalogue, establishing a unified national catalogue of reimbursable medical service items — starting with 13 clinical categories including cardiovascular, respiratory, ophthalmology, gynecology, radiotherapy, anesthesia, nursing, clinical scale assessment, dental implants, assisted reproduction, obstetrics, radiological examination, and rehabilitation — to be applied first to cross‑province direct settlement and then progressively aligned with provincial payment scopes.

Policy Snapshot

ItemDetail
AuthorityNational Healthcare Security Administration (NHSA), China
DocumentWork Plan for Formulating the First Batch of the National Basic Medical Insurance Medical Service Item Catalogue
Release Date16 September 2026
Legal BasisHealthcare Security Law of the PRC; CPC Central Committee & State Council Opinions on Deepening Healthcare Security System Reform; 1999 MOHRSS rules on diagnostic/treatment item management
First Batch Scope13 categories (incl. related items in other categories), to be expanded in batches alongside the national medical service price project listing guidelines
Initial ApplicationCross‑province direct settlement for out‑of‑town treatment; subsequently linked with provincial insurance payment scopes

Inclusion & Exclusion Criteria

  • Inclusion Baseline: Items must be listed in the current national medical service price project listing guidelines (trial), be clinically necessary, safe, effective and appropriately priced, and pose controllable impact on basic medical insurance fund expenditure without threatening fund security.
  • Explicit Exclusions: Items subject to market‑regulated pricing; non‑disease‑treatment services such as cosmetic procedures, weight loss, health checkups, prevention and wellness; services with insufficient clinical application, uncertain efficacy, or major safety risks; and anything else outside the basic insurance coverage scope.
  • Guiding Principle: The catalogue adheres to the “basic coverage” positioning of basic medical insurance — acting within capability, keeping total volume stable, and ensuring smooth transition, weighing fund affordability, clinical demand and social impact.

Work Program – Three Phases

  • Preparation Phase: Establish a dedicated task force and expert database; finalize work rules covering integrity, confidentiality and conflict‑of‑interest recusal; collect provincial data on price‑listing implementation, service pricing and payment status; and run fund modeling on the first batch’s insurance expenditure and the overall national cost envelope for medical services.
  • Review Phase: A survey across representative medical institutions at all levels in 31 provinces (regions, municipalities) plus the Xinjiang Production and Construction Corps; joint review by management and clinical experts scoring each item on inclusion merit, health benefit, clinical need, equity and cost‑effectiveness; expert discussion of restricted payment scopes; and a fund impact assessment with local insurance authorities before shortlisting items.
  • Publication Phase: The first‑batch catalogue is finalized based on expert opinions and fund impact modeling, submitted for approval per procedure, then issued to guide local implementation.

Governance & Expert Oversight

  • Expert Composition: Reviewers — insurance management, price management, health economics/HTA and clinical experts — are recommended by relevant departments or randomly drawn from the expert pool, with geographic balance, representation across institution types and tiers, and inclusion of primary‑care institution representatives.
  • Clinical Reviewer Scope: Clinical experts evaluate items only within their specialty fields.
  • Supervision Mechanisms: Disciplinary inspection and supervision bodies are invited to oversee preparation, review and publication; internal controls mandate role accountability, confidentiality, recusal and liability rules; experts sign non‑disclosure agreements, must commit to impartial service, are barred from unauthorized public activity in the catalogue‑expert capacity, and all proceedings are fully documented to preserve independence.

Market Impact & Outlook

  • Reimbursement Architecture: A unified national service catalogue replaces the current patchwork of provincial coverage lists — a structural shift for hospitals’ revenue predictability and for cross‑province settlement efficiency serving China’s large migrant population.
  • Provider Strategy: Medical institutions should map their service portfolios against the 13 first‑batch categories and the inclusion criteria, anticipating which items may face restricted payment scopes or exclusion as market‑priced services.
  • Sector Winners & Watchpoints: Categories inside the catalogue — notably dental implants, assisted reproduction, rehabilitation and radiotherapy — gain clearer reimbursement visibility, while cosmetic, wellness and weight‑loss services are explicitly ring‑fenced outside basic insurance.
  • Phased Expansion: Subsequent batches will follow the rollout of national price project listing guidelines, signaling a multi‑year build‑out toward full national standardization of insured medical services.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the formulation, approval and implementation of China’s national medical insurance medical service item catalogue. The work plan remains subject to consultation, expert review and fund impact assessment; the final catalogue composition, payment restrictions, effective dates and local implementation may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://ylbz.gansu.gov.cn/ylbzj/c105248/202609/174394881.shtml

China’s NHSA Publishes 21st Batch of Intelligent Supervision “Two Databases” Rules – Pushing Medical Insurance Fund Compliance to the Front End

Beijing, China – 11 Sep 2026 – The National Healthcare Security Administration (NHSA) has released the 21st batch of rules and knowledge points under its intelligent supervision “Two Databases” framework — the National Medical Insurance Fund Intelligent Supervision Knowledge Database and Rules Database (2025 Edition) — as part of a broader drive to help designated medical institutions master fund‑supervision rules, achieve proactive and continuous compliance through intelligent means, and shift regulatory oversight upstream.

Regulatory Milestone

ItemDetail
AgencyNational Healthcare Security Administration (NHSA), China
Action TypePublic release of intelligent supervision rules & knowledge points (Batch 21)
FrameworkMedical Insurance Fund Intelligent Supervision “Two Databases” – Knowledge Database & Rules Database (2025 Edition), now published and distributed
Scope of This BatchKnowledge‑point details for 9 chapters – including “Certain Infectious and Parasitic Diseases” – corresponding to the “Diagnosis Inconsistent with Patient Gender” rule
Mandate to Provincial AuthoritiesProvincial healthcare security departments must dynamically update the “Two Databases” in provincial intelligent supervision subsystems per the latest knowledge‑point details and codes
Feedback Channeljjjgs522@nhsa.gov.cn
AttachmentsBatch 21 knowledge‑point details in PDF and XLSX formats
Next StepsContinued batch releases and system integration; further batches’ content and timing Not disclosed

Policy Profile & Mechanism

  • Objective: The 2025 Edition was compiled by the NHSA to familiarize designated medical institutions and their staff with fund‑supervision rules, enabling automated, intelligent compliance rather than retrospective enforcement.
  • Rule Logic: The “Diagnosis Inconsistent with Patient Gender” rule flags billing or coding entries where a recorded diagnosis is clinically incompatible with the patient’s sex – a classic marker of miscoding or fraudulent claims.
  • Front‑Loading Oversight: The framework is designed to move the regulatory checkpoint upstream (“监管关口前移”), catching non‑compliant behavior at the “budding” stage before fund misuse occurs.
  • Batch Cadence: This release is the 21st batch in a systematic, chapter‑by‑chapter rollout of knowledge points – cumulative rule inventory and remaining batches Not disclosed.

Implementation Framework for Designated Institutions

  • Institutional Integration: Designated medical institutions may embed the “Two Databases” into their own intelligent reminder and information systems to run automated alerts and self‑inspection/self‑correction at the point of care and billing.
  • Direct System Linkage: Alternatively, institutions can connect to the NHSA’s intelligent supervision pre‑reminder function module, aligning internal workflows with the national oversight system.
  • Provincial Platform Updates: Provincial‑level intelligent supervision subsystems are required to refresh rules and codes on a dynamic basis, ensuring nationwide consistency of the enforcement logic.
  • Fraud Reporting Channels: The NHSA reiterates public reporting lines for suspected fraud against the medical insurance fund (hotlines 010‑89061396 / 010‑89061397; jubao@nhsa.gov.cn), underscoring the fund‑security mandate accompanying the release.

Market Impact & Outlook

  • Compliance Landscape: Hospitals, clinics, and pharmacies operating on China’s medical insurance reimbursement rails face increasingly automated, code‑level scrutiny of diagnoses and billing – raising the cost of compliance failures and the value of robust internal audit systems.
  • Health‑IT Opportunity: The requirement for institutions to integrate the “Two Databases” into intelligent reminder systems signals sustained demand for medical insurance compliance software and intelligent supervision solutions.
  • Enforcement Direction: Front‑loaded, rules‑driven supervision marks a structural shift from ex‑post punishment toward prevention‑first fund governance across the world’s largest basic medical insurance system.
  • Institutional Readiness: Providers that adopt pre‑reminder integration early can reduce recoupments and penalties; detailed penalty implications of the new rules – Not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the rollout of additional “Two Databases” batches, provincial system updates, institutional integration timelines, and enforcement outcomes under the NHSA’s intelligent supervision framework. Actual developments may differ due to policy adjustments, implementation variability across provinces, and institutional adoption factors.-China Health Reform Pulse

Policy Source: https://www.nhsa.gov.cn/art/2026/9/8/art_109_22052.html?sessionid=